International — RUNX1/ALSF 2027 Early Career Investigator Grants (Up to $180,000; December 17)

FundingUp to $180,000 per individual investigator project over three years; maximum $60,000 per year in eligible direct research costs. No indirect costs or tuition remission allowed. PI salary adheres to NIH salary cap; fringe, eligible travel, supplies, modest equipment and disclosed subcontracts may be budgeted. No mandatory cost-sharing rate stated.

DeadlineThursday, December 17, 2026 at 8:00 p.m. Eastern Standard Time (EST), as explicitly printed in the 2027 RUNX1 Early Career Investigator Grant guidelines.

Last verified2026-10-27

Required next actionReview official 11-page 2027 RUNX1 application guidelines at https://www.alexslemonade.org/sites/default/files/images/alsf1/downloads/2027_ecr_guidelines_final_9_2.pdf. Register ORCID and ProposalCentral account; prepare a single PDF no larger than 20 MB with budget/justification, scientific abstract, specific aims, approach, NIH SciENcv biosketches, resource sharing, clinical translation, applicable IRB/IACUC information, 3 recommendation letters, support documentation and certifications. Submit in ProposalCentral by December 17, 2026 at 8:00 p.m. EST; monitor confirmation.

Broad Eligibility

Nonprofit applicant institutions based in the U.S. OR other countries; investigator nationality unrestricted. Applicant PI with MD, PhD, MD/PhD, DO, MBBS or equivalent degree within 5 years of first Assistant Professor/equivalent faculty appointment; Associate/Full Professors ineligible. Instructors require mentor letter. Minimum 75% overall protected research time, demonstrated hematopoiesis or immunology expertise, scientific and financial nonoverlap. Projects must target prevention of hematologic transformation in RUNX1 familial platelet disorder.

Atlas Analysis

Funder controlling 11-page 2027 RUNX1 Early Career Investigator application guidelines reviewed October 27, 2026, including scope, eligibility, 3-year $180k award (max $60k annually), deadline Dec17 8pm EST, direct costs only, NIH salary cap, ban indirect and tuition, no published match, global nonprofit recipient eligibility, faculty within five years of first Assistant Professor rank (Instructor with mentor support), 75% protected time, normal/malignant hematopoiesis or immunology expertise, RUNX1-FPD focus, required sharing, progress/reporting, and annual RUNX1 scientific meeting. Human embryonic stem cell/nonhuman primate research prohibited; iPSC permitted. One resubmission allowed. Complete ProposalCentral application includes ORCID, one PDF <=20 MB, SciENcv, 3 recommendations, human/vertebrate approvals where relevant. Projected start April 2027. This is a distinct 2027 international research grant, not same as ALSF Young Investigator grant.

2027 RUNX1 Early Career Investigator Grant

The RUNX1 Research Program, together with Alex’s Lemonade Stand Foundation for Childhood Cancer, offers competitive grants supporting basic and translational scientific research aimed at preventing progression from pre-leukemia to blood cancer in people with RUNX1 familial platelet disorder (RUNX1-FPD). This is an applicant-facing research grant, not procurement. The 2027 application deadline is December 17, 2026 at 8:00 p.m. Eastern Standard Time.

Individual applicant funding

Up to $180,000 over three years, capped at $60,000 each year in eligible direct research costs. No indirect/overhead costs are permitted; investigator salaries must respect the NIH salary cap. Eligible costs include salary/fringe, travel, supplies, small equipment and justified subcontracts. Tuition remission is excluded. No universal mandatory cost-sharing or matching percentage is published. Funding depends on annual progress review; the grant is nonrenewable, with a possible no-cost extension request.

Who is eligible

Funds must go to nonprofit institutions or organizations, whether based in the United States or abroad. US citizenship is not required. The principal investigator must hold an MD, PhD, MD/PhD, DO, MBBS or equivalent degree and be within five years of the first Assistant Professor or equivalent tenure-track faculty appointment. Associate or Full Professors are ineligible; an Instructor-level applicant needs a mentor support letter. Investigators must devote at least 75% protected time to their overall research portfolio and demonstrate prior hematopoiesis or immunology expertise. Overlapping scientific or budget funding is prohibited.

Allowable science and limitations

Projects must address biological mechanisms and translation relevant to preventing hematologic malignant transformation in RUNX1-FPD, including clone targeting, inflammation, restoration of RUNX1 function and genomic instability. The research program prohibits studies using human embryonic stem cells or nonhuman primates; human induced pluripotent stem cells are permitted. A resource-sharing plan is mandatory. Recipients must provide progress reports and participate in the annual RUNX1 scientific meeting.

Application and documentation

Review the complete official 11-page 2027 application guidelines, then submit through ProposalCentral. ORCID registration is required. Upload a single combined PDF up to 20 MB containing the cover, table of contents, abstract, impact statement, budget and justification, NIH SciENcv biosketches, specific aims and research narrative, resource-sharing plan, clinical translation plan, relevant IRB/IACUC documentation, three recommendation letters and other required attachments. One resubmission is permitted under stated rules. The deadline is December 17, 2026 at 8 p.m. EST.

Controlling official instructions: RUNX1 2027 detailed grant application guidelines (11-page PDF). ALSF Early Career Research Programs.

Source verificationReferenced source · www.alexslemonade.orgAtlas last verified this record 2026-10-27. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗